HIV-1 infected patients who acquire HCV infection have higher rates of chronicity and liver disease progression than patients with HCV mono-infection. Understanding early events in this pathogenic process is important. We applied single genome sequencing of the E1 to NS3 regions and viral pseudotype neutralization assays to explore the consequences of viral quasispecies evolution from pre-seroconversion to chronicity in four co-infected individuals (mean follow up 566 days). We observed that one to three founder viruses were transmitted.
Hepatitis C virus quasispecies and pseudotype analysis from acute infection to chronicity in HIV-1 co-infected individuals
Transmission of HCV occurs in high risk groups often already burdened with other infections, notably HIV-1. This has now reached epidemic significance (Arends et al., 2015 , Fierer et al., 2008 , Gambotti et al., 2005 , Gilleece and Sullivan, 2005 , Thomson et al., 2009 , Turner et al., 2010 , Vogel et al., 2005 and the outcome of dual infection may be considerably worse than HCV infection alone (Chen et al., 2014 , Thomas, 2002 . The factors that influence HCV disease progression in HIV co-infected individuals are still poorly defined.
We hypothesized that most of the sequence evolution would occur in the HCV E2 envelope gene, specifically the hypervariable region 1 (HVR1, Bankwitz et al., 2010 , Farci et al., 2000 , von Hahn et al., 2007 . In addition to E2 we also investigated regions E1, p7, NS2
and NS3 in the plasma from four HCV/HIV co-infected patients at multiple time points from pre-seroconversion to at least eight months, post infection. The capacity of these viruses to induce host antibody neutralization was assessed using the HCV pseudotype particle (HCVpp) expression system (Bartosch et al., 2003a , Bartosch et al., 2003b including HCV seroconversion (anti-HCV), HCV RNA and genotype, ALT, CD4 T-cell counts, HIV-1 viral load and treatment history are summarised in Fig. 1 and Table 1. HCV infection was acquired by sexual transmission in all patients and there was no history of injecting drug use or other parenteral exposure. None cleared their HCV infection spontaneously during follow up (at least 8 months, Fig.1 ). For all patients a drop in HCV viraemia at or around anti-HCV seroconversion coincided with a peak ALT level. The latter probably reflected HCV infected cell death at around this time. A second rise in ALT (patient D) between Tp3 and Tp4 ( Fig. 1 ) was investigated by re-genotyping the HCV 5'untranslated region (UTR) region at these time points to exclude superinfection and all UTR sequences were identical. Additionally, comparison of all SGA variants generated from patient D revealed a 92-93 % similarity to the GenBank EU234064.2 sequence confirming the 1a genotyping and providing no evidence of superinfection. However, it is possible that superinfection with the same genotype may have occurred. Chronic HBV infection with low level HBV viraemia was also noted in patient B.
Overall HCV sequence diversity during the course of infection
Variant sequences from the four patients were analysed at several time points from early infection, between 18-42 days post the "estimated time of infection" (ETI-see below for definition) for Tp1, through to chronicity (follow up for 249-930 days; mean 566, Table 1 ).
Only single template variants were included in the final analysis and there was no evidence of recombination (P <0.05) in any of the variant sequences analysed. Due to sequence variability in parts of the genome, several different primers were required to amplify the E1-NS3 regions of HCV from the four patients (Table S1) and thus the precise location and length (bp) of the amplicons differed to some extent (Table S3 , column 6). A total of 241 SGA-derived variants were studied with a mean of 16 (range 9-23) sequences per patient per time point (Table S2 , column 5). Later time points showed higher numbers of mutations in accordance with the expected increase in genetic complexity over time, especially in variants analysed from patients B and D (Table S2 and highlighter plots, Fig. S1 ).
Analysis of transmitted/founder (T/F) viruses
Using the Poisson-Fitter model and a mutation rate of 2.5x10 -5 (Ribeiro et al., 2012 ) the viral diversity at Tp1 was analysed to examine whether the variants had a star-like (single T/F origin) distribution. One patient (M) revealed a non-star like pattern, patient B a near star-like pattern whereas two (D and C) had star-like phylogeny (Table S3 ). Unrooted tree analysis ( (Table S3 ) and approximately fitted the ETI for patients C, D and M (Table 1) . For patient B, instead of 30 days since the estimated time of infection, an MRCA value of 92 days was calculated. However, using a slightly higher mutation rate of 6.2x10 -5 , but within the reported range (Ribeiro et al., 2012) , the two values became compatible (37 days with a range of 33-42).
Pairwise t-test analysis of genetic distance (GD) values at Tp1 (Table S2 ) also confirmed that the population diversity of the virus in patient B was significantly greater (P <0.0001) at the 95% level, than in patients C, D and M. The variants present in patient M were also significantly more diverse than those in patients C and D (P < 0.012, <0.0003, respectively).
Viral diversity and the appearance of a "population bottleneck"
For patient B high variant diversity early on in the infection led, through a purifying selection, to a cluster of mainly homogeneous variants (a "bottleneck") which slowly diversified to give a heterogeneous collection of variants (Tp4) with three branches showing >70% bootstrap support (Fig. 3) . For patient D an increase in viral diversity occurred among the Tp4 variants ( Fig. 3 and Table S2 ). In contrast to the phylogenetic trees derived for patients B and D, the trees for patients M and C failed to show evidence of positive selection (Fig. 3) . The HCV sequences obtained at different time points from patients C and M were intermingled. It is noteworthy that of the three (T/F) viruses identified in patient M, only one gave rise to the sequences present at Tp2 and Tp3.
Highlighter plots (Fig. S1 ) and Shannon Entropy data analysis ( 
Amino acid changes within immune recognition and CD81 binding sites
To identify locations targeted by the immune response at T helper cell, B cell and CTL epitopes, HCV variant amino acid substitutions where selection occurred were recorded by HCV region (Tables 2 and 3 ). Single amino acid changes which were not observed at subsequent time points were not recorded as they were considered to have a neutral effect on virus fitness. For patient C only a few mutations occurred in the NS3 region but none of these variants became established. Thus a relatively stable population of HCV variants were present and the immune selective pressure on the virus was probably low. This patient was followed for only four months after HCV seroconversion and was treated successfully at around Tp4. Table 2) .
Phenotype of the E1 and E2 proteins from majority variants
A single majority variant was chosen as representative of the majority sequences at each time point by distance matrix analysis of the E1/E2 region. This variant was cloned, resequenced to confirm no errors had been introduced and expressed on the surface of retroviral To test if the HCVpp expressed proteins from different patients were susceptible to neutralization by a well-defined broadly neutralizing antibody, we assessed the ability of mouse monoclonal antibody AP33 (Owsianka et al., 2005) to inhibit entry. Despite the observed differences in their resistance to neutralization by patient plasma, all of the HCVpp tested were neutralized by mAb AP33 (Fig. 4C ). However, titration of the monoclonal antibody in these assays revealed subtle differences in the neutralization curves with the virus from patient B, B4 HCVpp-Tp4 being most resistant and the virus from patient C, C HCVpp, being most sensitive.
Discussion
Given the known impact of HIV infection on the natural history of HCV infection, we wished to explore the virus and immune system interactions following acute HCV infection in a group of HIV-1 infected patients. In HCV mono-infected patients, soon after the initial infection, HCV diversity increases especially in the E2 HVR (Brown et al., 2005 , Bull et al., 2011 , Casino et al., 1999 , D'Arienzo et al., 2013 , Farci et al., 2000 , Li et al., 2012 Sheridan et al., 2004 , Wang et al., 2010 . Initial transmission of limited numbers of viruses ("founders") is followed by purifying selection by the immune response and then a slow emergence of variants which become established. In HIV/HCV co-infected patients, Wang and colleagues (2010) reported lower diversity in the HVR1 in a cross sectional study using pyrosequencing. Reduced HCV genetic complexity was also reported in HVR1
comparing HIV-negative and co-infected patients (Lopez-Labrador et al., 2007 , Shuhart et al., 2006 . However, the impact of ART in co-infected patients has been reported to lead to increased quasispecies complexity (Rotman and Liang, 2009, Shuhart et al., 2006) . Gray et al. (2012) have proposed studying the dynamics of the entire HCV population structure, including liver as well as plasma populations, in order to understand more fully the complexities of HCV evolution.
In our study, soon after initial infection in two of the four patients (D, C) a set of closely related variants were identified. A broader more heterogeneous mix of variants were present in patient B but these three patients all showed a star-like, or near star-like, grouping of variants (suggesting single T/F viruses) using the Poisson-Fitter model (Fig. 2 , Table S3 ).
Patient M however, displayed variants derived from three T/F viruses. The route of HCV infection in all patients was by sexual transmission and these findings of single or few (three) T/F viruses are similar to other reports (Fierer et al., 2014 , Li et al., 2012 . Using t-test analysis of the GD at Tp1 (baseline) the variant diversity observed in patient B (Table S2) , was significantly greater than in the other three patients and subsequently only patient B evolved with a narrowing of diversity or 'bottleneck', (Fig. 3 , Table S2 ) where 62% of the virus variants were identical (Bull et al., 2011 , Li et al., 2012 , Ribeiro et al., 2012 . In agreement with other investigations, our study covering the E1 to NS3 regions revealed an absence of insertions, deletions and recombination hot spots (Fierer et al., 2014 , Shi et al., 2012 .
Spontaneous HCV clearance has been reported in co-infected patients with high CD4 and ALT values and low viral diversity in the E2 HVR1 region (Thomson et al., 2011) . None of the four study patients described here experienced spontaneous HCV clearance even though patients C and M did display low levels of viral diversity throughout follow up. The higher variant diversity which developed by Tp4 in the virus in patient B, may be associated with being on ART and the suppression of HIV replication (Table 1, Table S2 , Bernini et al., 2011 , Shuhart et al., 2006 . This case showed similar diversity to that reported in HCV mono-infected patients (Brown et al., 2005 , Bull et al., 2011 , Casino et al., 1999 , D'Arienzo et al., 2013 , Farci et al., 2000 , Li et al., 2012 Sheridan et al., 2004 , Shuhart et al., 2006 , Wang et al., 2010 . ART may have helped to reconstitute the immune response to HCV, even if not sufficient to control HCV replication (Bernini et al., 2011 , Herrero-Martinez et al., 2004 . CD4 T-cell values throughout follow up were no lower than 190 cells 10 6 /L in all patients (Table 1) and were considered not to play a role in the observed differences in diversity progression however the functionality of CD4 cells was not investigated. Shen and colleagues (2014) also reported that evolution was not influenced by CD4 levels. Lack of positive selection seen in the phylogenetic analysis of viruses from patients C and M may be associated with late seroconversion in (Table 1, 123 and 149 days, post ETI respectively) and/or the high HIV viral load at Tp1 (>5.0 log10 copies/ml). A recent Dutch study (Vanhommerig et al., 2014) reported a mean time to seroconversion of 74 days (IQR 47-125 days) in co-infected patients. Patient D, probably co-infected with HIV and HCV at the same transmission event, also showed a lack of viral sequence evolution. Positive selection was eventually observed two and half years after the ETI, at Tp4. The HIV viral load was > 3.72 log10 copies/ml throughout follow up. A second elevation in ALT (521 IU/ml) was noted at 814 days, post ETI (Fig. 1) . HCV superinfection at this time point was considered but no evidence of a switch in genotype or superinfection with the same genotype detected.
To assess the impact of the host responses on the HCV quasispecies we investigated the selection of amino acids variants that evolved at later time points. Of the four patients studied only patient B showed sufficient immune selection pressure on amino acids in the E2 region to drive change. These changes occurred progressively from Tp3 (270 days, post ETI)
to Tp4 (719 days post ETI) and by the end of follow up nine non-synonymous changes in the E2 region (six in the HVR1) were present. These changes were at known B cell, T helper cell, CTL epitopes and at the CD81 binding site. Positively charged amino acids appear to predominate at several E2 locations, H386, R408, H488 and R648 and may modify SR-B1-dependent entry (Koutsoudakis et al., 2012 , Sabo et al., 2011 . A K408Q substitution evolved in the virus isolated from patient B and perhaps affected SR-B1 mediated entry. Variants with H444Y, at a region involved in CD81 binding, also evolved and may influence HCV replication fitness (Deng et al., 2013a , Keck et al., 2009 , Pileri et al., 1998 .
Histidine (H) is unusual at this CD81 location as tyrosine (Y) is more commonly seen and basic residues (K, R and H) may protect against neutralizing antibodies (Boo et al., 2012 , Drummer et al., 2006 . The positively selected substitution I603V where convergent evolution was detected (Table 2) , is present in a ß-sheet of the core E2 domain (Kong et al., 2013 ) and this site is possibly linked with modulating E1/E2 conformation and virus entry (Douam et al., 2014) . Interesting no mutations were detected in the E2 412-424 linear epitope region which has been reported to be a major neutralization target (Owsianka et al., 2005 , Tarr et al., 2015 . 
Conclusion
This study, even though small, provides evidence for different patterns or mechanisms of HCV quasispecies evolution after sexual transmission in HIV infected MSM. In all four patients we identified T/F viruses (one to three), but in only one patient (B) was a population bottleneck and subsequent E2 region evolution observed. An improved immune response due to ART with the suppression of HIV replication at the time of HCV infection could have played a role in this instance. For the other three patients a limited increase in virus variant complexity emerged and notably in these cases the baseline HIV viral loads were greater than 4 log10 copies/ml. HCVpp neutralization studies first detected antibody neutralization at four, six and ten months after seroconversion and HCV variants displayed relative resistance to neutralization by autologous plasma. The greatest neutralization was observed with plasma from later time points. We speculate that after transmission, the evolution of HCV diversity may be influenced by the presence of unsuppressed HIV replication which compromises the host immune response. Further studies on larger patient cohorts would be required to confirm this speculation.
Material and methods

Ethics statement
This study was conducted on stored plasma samples sent for testing at UCLH as part of clinical care. All patients had been enrolled in the Acute Hepatitis C Cohort at the UCL Centre for Sexual Health and HIV Research Unit and written informed consent was gained from each patient. The samples and clinical data were all anonymized. min. This was followed by a second-round PCR where 1 µl of the first round product was transferred to 20 µl reaction mix which contained the second-round primers (genotype dependent, Table S1 ). The 20 µl reactions were performed with a master mix of 1x Platinum ® taq high-fidelity buffer, 2 mM MgSO4, 0.2 mM dNTPs, 0.025 units of Platinum ® taq high-fidelity DNA polymerase, 14.9 µl of water and 0.2 µM of each second-round forward and reverse primers (Table S1 ). The annealing temperature was changed to 64 o C for the secondround PCR. All other cycling conditions remained the same as those described for the firstround PCR. PCR products were analysed using 1.0% agarose E-gels ® (Life technologies TM ).
Study patients
SGA amplicons which were probable single templates were purified (QIAamp purification kit, Qiagen) prior to sequencing. Primers were designed or chosen (Table S1 ) to amplify the HCV E1 to NS3 regions from each patient. No one set of primers was able to amplify the virus from all four patients, thus products of between 2551-3161 bp were generated.
Similarly, when bi-directional sequencing was performed (3130xl Genetic Analyzer machine, Applied Biosystems ® ) primers were selected (eight used per amplicon) depending on the patient/genotype under investigation (Table S1 ).
Sequence analysis
Variant sequences were aligned using the Sequencher analysis software Giorgi et al., 2010) and to establish the sequence diversity and phylogeny. A mutation rate of 2.5x10 -5 mutations per nucleotide per genome replication (Ribeiro et al., 2012) was used in the sequence analysis for Tp1 samples. Unrooted tree analysis using http://www.hiv.lanl.gov/content/sequence/RAINBOWTREE (Fig. 2) at Tp1 was performed. Phylogenetic trees (Fig. 3) for all variants generated were built using the 
Majority sequence selection and HCVpp studies
Distance matrix analysis was used to identify the majority sequences for each patient at the selected time points. HCVpp expression and neutralization studies were performed as previously described (Tarr et al., 2007) . Briefly, the E1/E2 genes were amplified using the primers HCVppF and HCVppR (Table S1) Gambotti, L., Batisse, D., Colin-de-Verdiere, N., Delaroque-Astagneau, E., Desenclos, J. C., Dominguez, S., Dupont, C., Duval, X., Gervais, A., Ghosn, J., Larsen, C., Pol, S., Underlined mutation at E837V/K undergoes convergent evolution -posterior probability 0.97 using FUBAR algorithm of [dN>dS] >0.95.
Table 3
HCV epitope locations and CD81 binding sites where amino acids evolved. 
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